cmp
TRANSCRIPT
CARDIOMYOPATHY AND MYOCARDITIS
Guided by : Dr Sandeep agarwal
Presented by : Dr Abhay Pota
www.dnbpediatrics.com
Table of Contents
[A] CARDIOMYOPATHY
1.HOCM
2.DCM
3.RCM
4.LVNC
5.ARVC
6.EFE
[B] MYOCARDITIS
www.dnbpediatrics.com
[A] CARDIOMYOPATHY DCM
i) NMD – muscular dystrophies (duchene, becker, emery dreifuss, limb girdle etc)
- myotonic dystrophy
- myofibrillar myopathy
ii) IEM – fatty acid oxidation disorders
- carnitine abnormalities (CPT I, CPT II)
- mitochondrial disorders (kearns-sayre)
- organic acidemias (propionic acidemia)
iii) genetic mutation in cardiomyocyte structure
iv) genetic syndromes – alstrom syndrome, barth syndrome
v) ischemia – more common in adults
vi) chronic tachyarrythmias
www.dnbpediatrics.com
(2) HCM
i) IEM – mitochondrial disorders (freidrich ataxia), storage disorders
( esp. pompe, MPS, fabry, sphingolipidosis, hemochromatosis)
ii) genetic mutation in cardiomyocyte structure
iii) genetic syndromes- noonan, costello, cardiofaciocutaneous, beckwith- wiedemann
iv) infant of a diabetic mother
www.dnbpediatrics.com
(3) RCM
i) NMD- myofibrillar myopathies
ii) metabolic – storage disorders
iii) genetic mutations in cardiomyocyte structure
www.dnbpediatrics.com
iv) Arrythrogenic right ventricular cardiomyopathy
a) genetic mutation in cardiomyocyte structure
v) LV non compaction
b) X-linked, AR, AD, mitochondrial, sporadic
www.dnbpediatrics.com
[B] secondary or acquired myocardial disease
(1) MYOCARDITIS
i) viral
parvo bilateral, adeno, coxsackie A & B, echo, rubella, varicella, influenza, mumps
EBV, cytomegalovirus, mumps, measles, polio, Hepatitis C, HIV,
ii) rickettsial – psittacosis, RMSF, typhus, coxiella burnetti
iii) bacterial – diptheria, mycoplasma, meningococci, leptospira, lyme, typhoid, TB,
streptococci
iv) parasites – chagas, toxoplasma, cysticercosis, schistosomia
v) fungal – actino, coccidiomyco, histoplasmo
www.dnbpediatrics.com
(2) systemic inflammatory disease
SLE, scleroderma, churg-strauss RA, RF,
sarcoidosis, dermatomyositis, loffles
(3) Nutritional deficiency
Beri beri, kwashiorkor, keshan
(4) drugs
doxorubicin, chloroquine, cyclophosphemide, sulphonamides,
alcohol, irradiation, herbal remedy
www.dnbpediatrics.com
(5) CAD – kawasaki, ALCAPA, familial hypercholesterolemia
(6) Hemato-oncology – anemia, leukemia, SCD
(7) endocrine – neuroendocrine – hyperthyroidism,
carcinoid chromocytoma
www.dnbpediatrics.com
HOCM
It is a genetic disorder
Most common are mutations in genes encoding Cardiac B myosin
heavy chain (MYH7)Myosin binding protein C (MYBPC3)
AD pattern of inheritance
Other are PRKAG2 & LAMP2 α- galactosidase mutations
www.dnbpediatrics.com
PATHOGENESIS
Characterized by increased LV thickness in the absence of structural heart disease
or hypertension
Inter-ventricular septum is often disproportionately involved (IHSS) or (ASH).
In some patients intra-cavitary gradiant develops during systole.
This subaortic obstruction is caused by systolic anterior motion of mitral valve
against hypertrophied septum
Diastolic ventricular filling is impaired by abnormal stiffness of LV, which leads to LAH
and pulmo venous congestion, producing congestive symptoms
www.dnbpediatrics.com
a large volume of stroke volume (80%) is ejected during the early part of systole
when there is little or no obstruction, producing a sharp upstroke in the
arterial pulse- characteristic of HOCM
Because the obstruction of LVOT results from SAM of mitral valve against
hypertrophied septum, any influence that reduced LV systolic volume
(+ve inotropic agents, lowering of SVR. Low blood volume) will increase
obstruction and increase the murmur, while any influence that increases the
LV systolic volume (-ve inotropic agents, Leg raising, blood transfusion)
will decrease obstruction and decrease the murmur
www.dnbpediatrics.com
Clinical features
H/O : many patients asymptomatic
-50% cases present with heart murmur or detected
during family screening
-palpitation , chest pain, easy fatiguability,
-dyspnea, dizziness, syncope
-sudden death
www.dnbpediatrics.com
P/E
– over active pre-cordial impulse with a heave
abnormal PP
- Systolic ejection murmur in the aortic region
not associated with ejection click
- A sharp upstroke on arterial pulse
www.dnbpediatrics.com
ECG
– LVH, ST-T changes, abnormally deep Q waves
WPW syndrome in Danon and Pompe diasease
X-ray
- mild LVH with globular heart
- pulmo vascularity normal
www.dnbpediatrics.com
ECHO
Z Score of 2 or more relative to BSA is diagnostic
LV wall thickness Doppler helps in defining,
localising, quantifying the degree of myocardial
hypertrophy and also demonstrates degree of
LVOT and mitral insufficiency
Cardiac catheterization
Metabolic testing
Genetic testing www.dnbpediatrics.com
MANAGEMENT 1) sternous activity prohibited and rest
2) B blockers like propranolol or atenolol or CCBs
like verapamil, useful in diminishing LVOT,
modifying ventricular hypertrophy and
improve ventricular filling.
- Though, risk of sudden death not decreased.
3) antiarrythmic treatment in patient with atrial or ventricular
arrythmias
www.dnbpediatrics.com
4) patients with documented ventricular
arrythmias, strong family history or patients
with syncope – ICD
5) dual chamber pacing, alcohol ablation,
surgical septal myomectomy, MVR – limited success
6) first degree relatives should be screened every
3-5 years for patients under 12 years of age and
then yearly throughout the teenage and young adulthood
www.dnbpediatrics.com
PROGNOSIS
Children <1 year, with IEM or with some syndromes have poorer prognosis
Risk of sudden death is increased in patients with a History of cardiac arrest,
History of Vtach, Exercise hypotension, syncope>3 cm wall thickness,
F/H/O sudden death
www.dnbpediatrics.com
DCM
Most common form of cardiomyopathy
Most common cause of DCM is idiopathic
Among familial causes AD is most common
www.dnbpediatrics.com
PATHOLOGY AND PATHOPHYSIOLOGY
Weakening of systolic contraction
Dilatation of all 4 chambers
Dilatation of atria is in proportion to ventricles
(unlike RCM)
Intracavitary thrombus formation is common
in apical part of ventricles Pulmo& systemic emboli
On biopsy, myocyte hypertrophy and fibrosis
www.dnbpediatrics.com
CLINICAL FEATURES
history of – fatigue, weakness, dyspnea, orthopnea
P/E – s/o CHF (increased heart rate, crackles,
weak PP, distended neck veins, heapatomegaly)
Gallop rhythm, murmurs of MR or TR
www.dnbpediatrics.com
ECG
sinus tachycardia,
LVH & ST-T changes most common LAH,
RAH
Atrial or ventricular arrythmias
AV conduction disturbances
www.dnbpediatrics.com
x ray & echo
Cardiomegaly with or with out pulmonary edema
Echo – most important tool in diagnosis
pulmonary hypertension,
MR or other structural defects.
www.dnbpediatrics.com
Additional testing
CPK
KFT
LFT
Troponin
Lactate
plasma amino acids
urine organic acidsacylcarnitiine profile www.dnbpediatrics.com
MANAGEMENT
[1] medical treatment
Aimed at treating underlying heart failure
Diuretics, digoxin, ACEI, ARB
Bed rest and restriction of activity
Inotropic support and mechanical ventilation
www.dnbpediatrics.com
[2] B adrenergic blockade with carvedilol or metoprolol
Pediatric data not available
[3] ECMO, ventricular assist devices, cardiac transplantation
[4] specific antiarrythmic therapy and anticoagulation
www.dnbpediatrics.com
PROGNOSIS
1 and 5 year rates of death or need for transplantation in DCM
patients is 31% and 46%
Independent risk factors for death or need for transplant in DCM
patients are Older age, CCF Lower left ventricular functional
shortening zone
www.dnbpediatrics.com
RCM
<5 % of cases Incidence increases with age,
M<F Most common etiology is idiopathic
www.dnbpediatrics.com
PATHOGENESIS
Normal ventricular chamber diameter Normal ventricular wall
thickness Preserved systolic function Impaired ventricular filling
Normal size of ventricles with dilated atrias
www.dnbpediatrics.com
Clinical features
H/O : exercise intolerance, weakness, dyspnea, chest pain
P/E : jugular venous distention, gallop rhythm,
systolic murmur of AV valve regurgitation
ECG : bilateral AH, AV block
X-ray : cardiomegaly, pulmonary venous congestion
www.dnbpediatrics.com
ECHO : normal LV systolic function
diastolic dysfunction
bilateral AH with normal LV dimension
Cardiac catheterisation :
PApressure & RV & LV
EDP Increased
Endomyocardial biopsy
www.dnbpediatrics.com
MANAGEMENT
1)Treatment of CCF
2) CCB to increase diastolic compliance
3) anti-coagulants & anti-platelets to prevent thrombus
4) pacemaker for CHB5) cardiac transplantation
www.dnbpediatrics.com
www.dnbpediatrics.com
SUMMARY OF CLINICAL CHARACTERISTICS OF CARDIOMYOPATHY
CLINICAL FEATURES
HYPERTROPHIC DILATED RESTRICTIVE
CAUSE Inherited (AD in about 50%)Sporadic(new mutation)
Pluricausal (e.g.toxic metabolic, infectious, alcohol, doxorubicin
Myocardial fibrosis, hypertrophy, or unfiltration (amyloid hemochromatosis)
HEMO-DYNAMIC DYSFUNCTION
Diastolic dysfunction (with normal systolic function) (abnormally stiff LV with impaired ventricular filling
Systolic contractile dysfunction (decreased cardiac output, decreased stroke volume, increased LVEDP)
Diastolic dysfunction (rigid ventricular walls impede ventricular filling
www.dnbpediatrics.com
CLINICAL FEATURES HYPERTROPHIC DILATED RESTRICTIVE
Echo (morphology) Thickened LV (and occasionally RV) wall -Small or normal LV chamber dimensionsSupernormal LV contractility HOCM and/or ASH
Biventricular dilatation (increased LVDD and LVSD)-atrial enlargement in proportion to ventricular enlargement -Decreased LV contractility Apical thrombus(+/-)
Biatrial enlargement -Normal LV and RV volume Normal LV systolic function until advanced stage Atrial thrombus(+/-)
Doppler Reduced relaxation pattern Reduced relaxation pattern ‘reestrictive’ pattern
Treatment B-adrenoreceptor blockers -calcium antogonists(digitalis/catechols and nitrates contraindicated)- (diuretics may worsen the symptoms)
Vasodilator therapy -digitalis plus diuretics B-adrenoreceptorblockers(+/-)-Anticoagulants antiarrythmicsCardiactransplantation
Diuretics-Anticoagulants(+/-)-corticosteroids(+/-)-permanent pacemaker for advanced heart blockCardiactransplantation
www.dnbpediatrics.com
4. LVNC Left ventricular non compaction
affects all ages
Trabeculated or spongy appearing LV,
commonly a/w LVH or LV dilatation, and, at times systolic or diastolic dysfunction
ECG – LVH, ST-T changes or arrythmias
MRI – trabeculated LV myocardium,
characteristically within apex of left ventricle
Metabolic screen – especially in young patients TA2 gene mutation
www.dnbpediatrics.com
TREATMENT
anticoagulation, anti-arrythmic treatment if needed &
treatment of HF if present
Cardiac transplantation in patient refractory to medical treatment
www.dnbpediatrics.com
5. ARVC
-Arrythmogenic right ventricular cardiomyopathy
-AD from most common
-AR forms a/w skin manifestations
-Characterized by dilated RV with fibrofatty
-infiltration of RV wall
-Global and regional right and left ventricular dysfunction and
-ventricular tachyarrythmias
-Syncope or sudden death can be the presentation
-Mx - antiarrythmics, defibrillation and Mx of HF, Cardiac transplantation www.dnbpediatrics.com
[6] EFE
endocardial fibroelastosis
Incidence markedly decreased due to abolition of mumps virus inf by immunisation
Characterized by opaque, white, fibroelastic thickening on the endocardial surface
of the ventricle, which leads to systolic or diastolic dysfunction
Mx of HF & cardiac transplantation
www.dnbpediatrics.com
MYOCARDITIS
www.dnbpediatrics.com
Definition and Etiology
Process characterized by inflammatory infiltrate of the
myocardium with necrosis and/or degeneration of adjacent
Myocytes, not typical of the ischemic damage associated with
coronary artery disease
Most cases from common viral infections and post-viral immune
-mediated responseCoxsackievirus A and B, echovirus, poliovirus,
PVB 19, HHV6Precursor of dilated cardiomyopathy
www.dnbpediatrics.com
Etiology
www.dnbpediatrics.com
www.dnbpediatrics.com
Time Course of Viral Myocarditis
www.dnbpediatrics.com
Incidence
Often not recognized
Estimated annual incidence of 1/100.000
4 – 5% in young accident victims
12% in adolescents and young adults with sudden cardiac death
www.dnbpediatrics.com
Clinical features
H/O : URTI in older children or may have a sudden onset with
anorexia , vomiting, lethargy.
In new borns and infants signs of CHF like tachycardia, tachyapnea,
gallop rhythm, and arrythmia may be present.
A soft systolic heart murmur and supra ventricular or
ventricular ectopic beats may be present
www.dnbpediatrics.com
Laboratory Tests
Biomarkers (troponins, creatine kinase MB) occasionally elevated in childhood
(sensitivity 71%, specificity 86%)
Normal nonspecific markers of inflammation (CRP, leucocytes) do not exclude
acute myocardial inflammatory process
Utility of virus serology in patients with suspected myocarditis unproven –
costly and unreliable
• Detection of viral genome in urine or feces
www.dnbpediatrics.com
ECG
Abnormalities present in 93-100%, but low sensitivity
Sinus tachycardia
Nonspecific T-wave and ST-segment changes
ST-segment elevation
AV conduction delays
Atrial and ventricular arrhythmias
www.dnbpediatrics.com
ECG
www.dnbpediatrics.com
Chest X-ray
www.dnbpediatrics.com
Echocardiography
www.dnbpediatrics.com
MRI
www.dnbpediatrics.com
Endomyocardial Biopsy
www.dnbpediatrics.com
Endomyocardial Biopsy
Is a Gold standard for diagnosis
Invasive, potential complications: pneumothorax, hemothorax, arrhythmias,
perforation, death
Enables identification of lymphocytic invasion and detection of involved virus
Poor sensitivity and specificity due to patchy myocardial inflammation
Substantial interobserver variation
www.dnbpediatrics.com
Histology/Dallas Criteria
Acute myocarditis: lymphocytic infiltrate with myocyte necrosis
Borderline myocarditis: inflammatory infiltrate without necrosis
Chronic myocardits/DCM with inflammation:
>14 inflammtory cells/mm2 in the myocardium
www.dnbpediatrics.com
Differential Diagnosis
Any disease with impairment of LV function
DCMA
LCAPA
Chronic tachycardia
Arteriovenous malformation
www.dnbpediatrics.com
Therapy IMainly supportive, no trials for specific heart failure therapy in biopsy-proven
myocarditis in adults and children
Monitoring of vital parameters
Bed rest initially, no physical activities for 3-6 months
Trat heart failure therapy with ACE inhibitors, AT1-antagonists ß-blockers,
diuretics and aldosterone antagonists according to current guidelines
Ventricular assist device <-> HTX
Therapy of tachyarrhythmias in adults - Life vest and AEDwww.dnbpediatrics.com
Therapy II
In proven viremia: immunoglobulins 2 g/kg for 48 hours (Robinson JL 2005)
No immunosuppresive therapy – risk of enhanced virus replication and
blockade of endogenous interferons
Steroids only in biopsy-proven virus negative chroniC myocarditis (Frustacci A 2009)
Type-1 interferon (IFN-α, IFN-ß) beneficial in animal and human pilot studies
(Kühl U 2003, Schmaltz AA 1998)
www.dnbpediatrics.com
Acute Congestive Heart Failure/Suspected Acute Myocarditis
www.dnbpediatrics.com
REFERENCES
TEXTBOOK OF PEDIATRIC CARDIOMYOPATHY – S. PARKS 6th edition
NELSON – 19th editionE-medicine.medscape.com
www.dnbpediatrics.com
www.criticalpediatrics.org